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ABSTRACT
The genome of influenza A virus consists of eight
single-stranded RNA molecules of negative polarity.
Their replication and transcription take place in the
nucleus of infected cells using ribonucleoprotein
complexes (RNPs) as templates. Two of the viral
transcripts, those generated by RNPs 7 and 8, can
be spliced and lead to two alternative protein
products (M1 and M2, NS1 and NEP/NS2, respec-
tively). Previous studies have shown that when
expressed from cDNA, NS1 protein alters the
splicing and transport of RNA polymerase II-driven
transcripts. Here we used a transient replication/
transcription system, in which RNP 8 is replicated
and transcribed by recombinant RNA and proteins,
to study the splicing and nucleo-cytoplasmic trans-
port of true viral transcripts. Our results show that
the encoded NS1 protein inhibits the splicing of the
collinear transcript. This regulation is mediated by
the N-terminal region of the protein but does not
involve its RNA-binding activity. We also show
that NS1 protein preferentially blocks the nucleo-
cytoplasmic transport of the collinear RNP 8
transcript in an RNA-binding dependent manner.
These results rule out previous models to explain
the regulation of mRNA processing and transport by
NS1 and underlines the relevance of NS1 protein in
the control of virus gene expression.
INTRODUCTION
The inﬂuenza A viruses are members of the family
Orthomyxoviridae with a genome consisting of eight
single-stranded RNA segments of negative polarity. Each
one is encapsidated by binding to the polymerase complex
and to a number of nucleoprotein (NP) monomers (1),
forming a ribonucleoprotein (RNP) complex (2).
Transcription and replication of each virus RNP take
place in the nucleus of the infected cell [reviewed in (3)]
and hence viral mRNAs are potential substrates for the
cellular splicing machinery and need to be exported from
the nucleus to express the viral proteins. Indeed, the
collinear transcripts from segments 7 and 8 can be directly
expressed or can become spliced to generate M1 and M2
or NS1 and NEP(NS2) proteins, respectively (4–7). In
productively infected cells, these splicing events are
regulated in such a way that the steady-state ratios of
spliced versus non-spliced mRNAs is only a few percent
[reviewed in (8)]. These relative levels can be modiﬁed in
non-productive cells (9) or by virus mutation (10) and are
not constant along virus infection (11), suggesting the
involvement of virus and cellular factors in the regulation
of virus mRNA splicing.
The NS1 protein is a crucial regulatory factor during
virus infection [reviewed in (12–14)], aﬀecting cellular and
viral gene expression and virus counteraction of the
interferon response. It accumulates in the nucleus early
during virus infection (15) and when expressed from
cloned DNA (16–18), but it can be found in association
with polysomes later in the infection (19,20). NS1 is a
RNA-binding protein that interacts in vitro with dsRNA
(21,22), vRNA (23,24), poly-A-containing RNAs (25) and
U6 snRNA (26). The RNA-binding domain is located
within the N-terminal half of the protein (24,27), and the
rest of the protein appears to contain an eﬀector domain
(28). NS1 protein interacts with many viral and cellular
factors. These include the virus RNP and/or polymerase
(29), cellular proteins involved in translation, like
hStaufen, PABPI and eIF4G (20,30–32) and cellular
factors involved in post-transcriptional processing of
RNA, like CPSF (33), PABPII (34) and NS1–BP, a
potential splicing-related factor (35).
The splicing of NS1 mRNA has been studied in vitro.
Early work indicated that it is a non-spliceable transcript
under normal in vitro conditions (36), due the block after
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mapping experiments led to the identiﬁcation of RNA
sequences within NS1 mRNA that may down-regulate its
splicing eﬃciency (38). In vivo studies have also been
carried out to analyze the splicing of NS1 mRNA. When
expressed from a RNA PolII-driven cDNA it can be
spliced (16,39) and its splicing can be blocked in trans by
the expression of the encoded NS1 protein (40,41).
In addition of the splicing inhibition, PolII-driven
expression of NS1 from a cDNA led to a general retention
of mRNAs in the nucleus (25,28,41). The interaction of
NS1 with the CPSF polyadenylation factor (33) suggested
a mechanism for this transport block, as NS1–CPSF
interaction would inhibit the 30-processing of cellular
transcripts. Furthermore, it was proposed that CPSF
interaction would indirectly down-regulate the splic-
ing of cellular, but not viral, single-intron containing
transcripts (42).
The main limitation of these in vivo studies is that NS1
expression was carried out by transfection and the ‘viral’
mRNAs analysed are indeed PolII-driven transcripts. To
avoid these problems we have established a transient virus
replication-transcription system in vivo in which a
recombinant NS RNP is ampliﬁed and transcribed by
the viral polymerase. Using this more physiological system
we show here that NS1 protein down-regulates the splicing
and block the nuclear export of its own viral mRNA.
Furthermore, we report a genetic analysis of the roles of
the various NS1 domains for such regulation.
METHODS
Biological materials
The origin of the HEK293T cells (43) has been described
previously (44). The cells were cultivated as described (45).
The pHH plasmid containing the NS cDNA of
A/Victoria/3/75 strain RNA under control of the polI
promoter has been described (44). The antisera speciﬁc for
NS1 and NEP(NS2) proteins were generated by hiper-
immunization of rabbits or rats with puriﬁed proteins.
Invitro mutagenesis andplasmid constructions
To generate mutant plasmid pHHNS1, a site-directed
mutagenesis was carried out on plasmid pHHVicNS (46)
using the QuickChangeTM kit from Stratagene and the
following mutagenic oligonucleotides: NS1mut1 (50GCT
TCCTTTGGCATGTCTGATAACAAATTGTAGACC
AAGAACTAGG30) and NS1mut2 (50CCTAGTTCTT
GGTCTACAATTTGTTATCAGACATGCCAAAGG
AAGC 30). In this way, two successive stop codons were
introduced in the NS1 reading frame within the intron
sequence. Likewise, a NS1 mutant plasmid was generated
in which RNA binding is abolished (pHHVicNSR38A/
K41A) (22,47), using the following mutagenic oligonu-
cleotides: NS1mut3 (50TCGGCTTCGCGCAGATCAG
GCGTCCCTAAGG30) and NS1mut4 (50CCTTAGG
GACGCCTGATCTGCGCGAAGCCGA30).
Protein analyses
For protein labelling in vivo, cultures were washed,
incubated for 30min in a DMEM medium lacking
met-cys and labelled for 1h at 36 hours post-transfection
with
35S-met-cys to a ﬁnal concentration of 200mCi/ml
(48). Total extracts were prepared in Laemmli sample
buﬀer and processed by polyacrylamide gel electrophor-
esis and autoradiography.
Immunoprecipitation was carried out as described (44).
Protein-A-Sepharose immune matrices were prepared with
rabbit anti-NS2 IgG and were incubated with soluble cell
extracts prepared in 100mM NaCl-1mM EDTA-50mM
Tris–HCl-1% NP40, pH 7.5. After washing with the same
buﬀer, the bound material was eluted in Laemmli sample
buﬀer and processed by polyacrylamide-gel electropho-
resis and autoradiography.
For immunoﬂuorescence, transfected or mock-
transfected HEK293T cells were washed with PBS, ﬁxed
for 20min with 3% paraformaldehyde at room tempera-
ture and permeabilized with 0.5% Triton X100 for
5min. The cells were blocked with PBS-3%BSA and
incubated with rat anti-NS1 serum diluted in PBS-0.1%
BSA, for 1h at room temperature. After washing with
PBS, the bound antibodies were revealed with FITC-
conjugated goat anti-rat antibodies, by incubation for 1h
at room temperature. Finally, the cells were washed with
PBS and the preparations were mounted with Mowiol.
Images were obtained using a Leica ﬂuorescence
microscope.
For western blot analysis, cell extracts were separated
by polyacrylamide–SDS gel electrophoresis and trans-
ferred to Immobilon ﬁlters. The ﬁlters were blocked for 1h
at room temperature with PBS-3% BSA and incubated
with the primary antibodies diluted in 0.1% BSA-0.05%
Tween-20 in PBS, for 1h at room temperature. After
washing four times for 15min with 0.25% Tween-20 in
PBS, the ﬁlters were incubated with a dilution of goat anti-
rabbit or anti-mouse IgG conjugated to horseradish
peroxidase in 0.1% BSA-0.05% Tween-20 in PBS. After
washing in PBS, the ﬁlters were developed by enhanced
chemiluminiscence.
RNA analyses
The transfected or mock-transfected cells were washed
with PBS and collected by centrifugation for 5min at
2500r.p.m. The isolation of total RNA was carried out
using ULTRASPEC RNA Isolation Reagent (Biotecx,
Houston, TX, USA) according to the manufacturer’s
instructions. For cell fractionation, the cultures were
resuspended in isotonic buﬀer (150mM NaCl-1.5mM
MgCl2-10mM Tris–HCl-0.5% NP40-2mM VRC-1 mM
DTT, pH 8.5) and the nuclei were separated by
centrifugation for 5min at 3000r.p.m. and 48C. After an
additional wash in the same buﬀer, the supernatants were
pooled as cytoplasmic fraction and the pellet was used as
nuclear fraction. The extraction of RNA from the nuclear
fraction was carried out as indicated above for total RNA.
For RNA extraction from the cytoplasmic fraction it was
incubated with proteinase K (1mg/ml) in 100mM NaCl-
50mM Tris–HCl-5mM EDTA-0.5% SDS, pH 7.5)
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isoamylalcohol and recovered by ethanol precipitation.
The nucleic acids were digested with RNAse-free DNAse
(1U/mg RNA) and further extracted with phenol-
chloroform-isoamylalcohol and precipitated with ethanol
as above. Quantitation of ribosomal RNAs and ribosomal
RNA precursors in the subcellular fractions indicated
that around 80% of total cell rRNAs were present and no
rRNA precursors could be detected in the cytoplasmic
fraction.
Puriﬁcation of polyA-containing RNA was carried out
by oligo-dT cellulose chromatography. RNA samples
were resuspended in 0.5% sarkosyl in DEPC-treated H2O
and boiled for 3min. After dilution in 0.5M NaCl-10mM
Tris–HCl-0.5% sarkosyl, pH 7.5, the samples were applied
to the column and incubated for 1min. The ﬂow-through
was re-applied again and the column was washed with the
same buﬀer. The polyA-containing RNA was eluted in
two steps by washing ﬁrst with 0.5% sarkosyl and then
with DEPC-treated H2O. Finally, the polyA-containing
RNA obtained was boiled again and used as input for a
second step of oligo-dT cellulose chromatography as
above, to ensure the removal of viral genomic RNAs
complementary to the virus mRNAs. To control the
recovery of the oligo-dT cellulose chromatography a
known amount of a polyA-containing labelled riboprobe
was added and the radiactivity present in the various
fractions was determined. An average recovery of 75%
was obtained in the experiments carried out.
To determine the stability of NS1 and NEP(NS2)
mRNAs, actinomycin D (50mg/ml) was added to the
transfected cells at 36h post-transfection and total RNA
was isolated at various times thereafter. PolyA-containing
RNA was puriﬁed and the accumulation of NS1 and
NEP(NS2) mRNAs was determined by RNAse-protection
assay.
For RNAse-protection assay, the polyA-containing
RNA samples were co-precipitated with a molar excess
of labelled riboprobe and resuspended in 400mM
NaCl-40mM Pipes-5mM EDTA-80% deionised forma-
mide, pH 6.4. After denaturation for 5min at 858C,
hybridization was carried out overnight at 508C. The
mixture was diluted in a RNAse solution containing
300mM NaCl-5mM EDTA-10mM Tris–HCl, pH 7.5,
50mg/ml of RNAse A and 1u/ml of RNAse T1 and
incubated for 2h at 378C. After proteinase K/SdS treat-
ment as indicated above, phenol extraction and ethanol
precipitation, the samples were resuspended in formamide
loading buﬀer and analysed by polyacrylamide-urea gel
electrophoresis and autoradiography. Quantitation was
performed in a phosphorimager.
RESULTS
A transientreplication–transcription system toanalyse
virus mRNA processing and transport
The aim of this work was the analysis of the splicing and
nucleo-cytoplasmic transport of inﬂuenza virus mRNA,
independent of other virus processes but nevertheless in a
virus-like environment. To this aim we set up a transient
viral replication–transcription system in which the gen-
eration of the viral transcripts would be driven by the
normal virus machinery. As previous work of several
groups has implicated NS1 protein in the control of
mRNA maturation and transport, we expressed the
polymerase and NP by RNA PolII-driven transcription
and a segment 8 genomic RNA under control of an RNA
PolI promoter (Figure 1A). In this way, the consequences
of NS1 expression on the splicing and nucleo-cytoplasmic
transport of segment 8-speciﬁc mRNAs could be analysed
Figure 1. A transient replication-transcription system with a recombi-
nant NS replicon. (A) Diagram showing the process for reconstitution
of a recombinant NS replicon in HEK293T cells. Transfection of the
polymerase expression plasmids (PB1, PB2 and PA) and NP expression
plasmid, as well as the NS segment genomic plasmid (pHHNS) leads to
the replication and expression of NS RNPs. The process results in the
expression of NS1 and NEP(NS2) proteins. (B) Structure and proper-
ties of the NS1 proteins expressed from the NS replicons used in this
study. The location of the RNA-binding domain (RBD), eﬀector
domain (ED), eIF4G-binding domain (eIF4G-BD), the nuclear
localization signals (NLS-1 and NLS-2), the nuclear export signal
(NES) and the splicing sites (50-ss and 30-ss) are indicated. The position
of translation stops introduced by mutation in NS1 and NS1 81
mutants are indicated. The point mutations present in mutants
R38AK41A and 11C are indicated by asterisks.
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when the synthesis of NS proteins was determined in
cultures transiently replicating and transcribing a recom-
binant NS replicon a clear signal for both NS1 and
NEP(NS2) proteins was observed (Figure 2; wt) and the
accumulation of NS1 and NEP(NS2) proteins were
veriﬁed by western-blot or immunoprecipitation using
speciﬁc antibodies (Figure 3A, B; wt). Both the synthesis
and accumulation levels were similar to those obtained in
a normal infected cell (data not shown). This experimental
setting allowed the genetic analysis of the implication of
NS1 protein in viral mRNA maturation and transport by
simply mutating the replicon included in the system. Thus,
a number of altered replicons in which NS1 had been
mutated or replicons derived from NS1 mutant viruses
(44,46) were prepared and their genotype is described
schematically in Figure 1B. Mutant NS1 contained two
stop codons close to the N-terminus of the protein but
22nt away from the splicing 50-donor site, leading to the
synthesis of a 18 amino acids long peptide. Accordingly,
neither synthesis nor accumulation of NS1 protein was
observed in the system with this replicon (Figures 2 and
3A), while the synthesis of NEP(NS2) protein was still
detectable (Figures 2 and 3B). Likewise, NS1 mutants
lacking the eﬀector domain (NS1 81) or devoid of RNA-
binding activity (NS1 R38A/K41A) and mutants with ts
phenotype (NS1 81 and NS1 11C) could be expressed in
the system and showed expression levels according
to the described phenotypes (Figures 2, 3A–C) (44,46).
Furthermore, immunoﬂuorescence studies indicated that a
large fraction of the cultures in which the NS replicons
had been transiently established showed NS1 expression
(Figure 4), allowing biochemical analysis of the transcripts
generated. In these cultures, the levels of NS1 expression
were similar to those observed during infection and most
of the signal was found in the nuclei of the cells (Figure 4).
The stability ofNS segment mRNAs isindependent of NS1
protein expression
To study the potential role of NS1 protein in the
maturation and transport of NS segment transcripts we
ﬁrst determined whether the expression of NS1 could alter
the stability of the collinear or spliced mRNAs, encoding
NS1 and NEP(NS2) proteins, respectively. Total cell
Figure 3. Expression of viral genes encoded in the recombinant
replicons. Cultures of HEK293T cells were transfected with the
appropriate plasmids to establish the indicated wt or mutant NS
replicons or mock transfected (Mock). (A) At 36h post-transfection,
total cell extracts were prepared and analysed by western blot using
NS1-speciﬁc antibodies. To control the loading, a western-blot against
actin was used. The position of NS1 and actin proteins is indicated to
the right. The NS1 81 mutant protein was not detectable with the
antibody used. The mobility of molecular weight markers is shown to
the left. (B, C) At 36h post-transfection, the cultures were pulse-
labelled with
35S-met-cys as indicated in the legend to Figure 2 and
soluble cell extracts (T) were prepared. The extracts were immunopre-
cipitated with anti-NEP(NS2) (I) or with control antibodies (C) and the
products were analysed by polyacrylamide gel electrophoresis and
autoradiography. The position of NEP(NS2) and NS1 proteins is
indicated to the right. The mobility of molecular weight markers is
shown to the left.
Figure 2. Synthesis of NS1 and NEP(NS2) proteins from the
recombinant replicons. Cultures of HEK293T cells were transfected
with the appropriate plasmids to establish the indicated wt or mutant
NS replicons or mock transfected (Mock). At 36h post-transfection,
the cultures were pulse labelled with
35S methionine-cysteine and whole
cell extracts were analysed by polyacrylamide gel electrophoresis and
autoradiography. Cells containing the NS1 81 or the 11C replicons were
incubated at either permissive (32) or restrictive (39) temperature. The
position of the relevant proteins is indicated to the right. The mobility
of molecular weight markers in shown to the left.
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replicons had been established, prior to and at various
times after actinomycin D chase. The polyA-containing
fraction of these preparations was analysed by RNAse-
protection assay using a probe that could distinguish
collinear, unspliced mRNA from the spliced transcript.
The results are shown in Figure 5 and indicate that the
presence or absence of NS1 did not alter the half-lives of
NS1 or NEP(NS2) mRNAs. Therefore, we can use the
relative accumulation of NS1 versus NEP(NS2) tran-
scripts as a measure of the extent of NS collinear mRNA
splicing.
The N-terminal region ofNS1 protein issufficient for the
down-regulation of NS collinear mRNAsplicing
To determine the extent of splicing of NS collinear
transcript we establish the various NS replicons by
transfection of cultures of HEK293T cells as described
above. Total cell RNA was isolated and the polyA-
containing RNA fraction was puriﬁed and analysed by
quantitative RNAse-protection assay. The conditions of
the assay were set to ensure an excess of probe for all
samples. The results of a representative experiment are
presented in Figure 6 and Table 1 summarizes the data
obtained from three independent experiments. When wt
NS replicon was used, both NS1 collinear and NEP(NS2)
spliced mRNAs were detected and an extent of splicing of
around 45% was obtained (Figure 6, wt; Table 1).
However, deletion of NS1 led to dramatic change in the
splicing eﬃciency, as almost no collinear transcript could
be detected (Figure 6, NS1; Table 1). These results
indicate that NS1 protein down-regulates the splicing of
its own mRNA.
Figure 5. Stability of NS-encoded viral mRNAs. (A) Cultures of
HEK293T cells were transfected with the appropriate plasmids to
establish the wt or NS1 NS replicons. At 36h post-transfection,
actinomycin D was added to the cultures and total RNA was extracted
at the times thereafter indicated in the Figure. The poly A-containing
RNA was selected by oligo dT-cellulose chromatography and the
amounts of NS1 and NEP mRNA were determined by RNAse-
protection assay. The results from two independent experiments are
shown and the half-lives obtained from each experiment are presented
in the part B of the Figure.
Figure 4. Intracellular localization of NS1 protein expressed from
recombinant NS replicons. Cultures of HEK293T cells were transfected
with the appropriate plasmids to establish the indicated wt or mutant
NS replicons or mock transfected (Mock). At 36h post-transfection, the
cultures were ﬁxed and processed for immunoﬂuorescence using anti-
NS1 serum (NS1). The cultures were counterstained with Dapi to reveal
the nuclei (Dapi). Cells containing the NS1 81 or the 11C replicons were
incubated at either permissive (32) or restrictive (39) temperature.
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C-terminal eﬀector domains in NS1 are involved in this
down-regulation we determined the splicing phenotypes of
mutants aﬀected in either one. Mutant NS1 81 (44) lacks
the sequences 81-238 in NS1 protein and hence does not
contain the eﬀector domain. The NS1 81 mutant virus is
temperature-sensitive and shows a major defect in late
gene expression and minor reduction in vRNA replica-
tion. Therefore, we examined the splicing of transcrips
from a NS1 81 replicon at both permissive (328C) and
restrictive (398C) temperatures. The extent of splicing
at permissive temperature was similar to wt (Figure 6,
NS1 81; Table 1), and therefore we can conclude that
the N-terminal region of NS1 protein is suﬃcient for
down-regulation of the splicing of its own mRNA and the
C-terminal eﬀector domain is not required for such
function. Although splicing eﬃciency was reduced at
restrictive temperature (Figure 6, NS1 81; Table 1),
the wt replicon showed the same decrease (Figure 6, wt;
Table 1), indicating that this eﬀect is not due to the
mutation. Such a reduction for the wt replicon could be
the consequence of a low-splicing eﬃciency of the cell
machinery at high temperature, as the corresponding wt
recombinant virus showed reduced replication at 398C
(46), or may be connected to the temperature-sensitivity of
vRNA replication reported earlier (49).
In view of these results we tested whether the NS1
RNA-binding activity, which has been mapped to the
N-terminal half of the protein (22,24,50), is required
to down-regulate NS1 mRNA splicing. Mutations R38A
and K41A, known to abolish NS1–RNA binding (22,47)
were introduced in the NS replicons and the ratio of NS1
versus NEP(NS2) mRNAs was determined in cells in
which the mutated replicon had been established. The
results are presented in Figure 6 and Table 1 and show
that essentially no splicing of the NS collinear transcript
is observed. Thus, we can conclude that RNA-binding
by NS1 protein is not necessary for it to down-regulate
the splicing of its own mRNA and a mutant lacking
RNA-binding activity behaves as an highly eﬃcient
blocker of NS1 mRNA splicing. The splicing eﬃciency
of NS1 ts mutant 11C (V18A, R44K, S195P) was similar
to that observed for mutant NS1 81 (data not shown).
The NS1 proteinpreferentially blocks nucleo-cytoplasmic
transport of NScollinear mRNA
The transcription, maturation and nucleo-cytoplasmic
transport of mammalian mRNAs are linked processes
and inﬂuenza virus transcription depends functionally and
structurally on the cellular transcription apparatus
(51–53). In view of the alterations induced by NS1 in the
splicing of NS transcripts we seeked for potential changes
in the nucleo-cytoplasmic transport of these mRNAs. The
various NS replicons described above were established in
HEK293T cell cultures and nuclear and cytoplasmic
fractions were prepared. The polyA-containing RNAs
from these fractions were isolated and the recovery of
NS1 and NEP(NS2) mRNAs was determined in each
fraction by quantitative RNAse-protection assay. The
results of a representative experiment are presented in
Figure 7 and the data obtained from three independent
experiments is summarized in Table 2. The distribution
of these mRNAs in both cellular fractions indicated
that nucleo-cytoplasmic export was more eﬃcient for
the spliced NEP(NS2) than for the collinear NS1 mRNA
(Figure 7, wt). When NS1 expression was abolished, most
of the transcript was spliced and eﬃciently exported to the
cytoplasm (Figure 7, NS1). However, the collinear NS1
mRNA generated by the R38A/K41A mutant replicon,
which constitutes most of the NS transcript produced (see
Figure 6) was exported very eﬃciently (Figure 7, R38A/
K41A). Therefore, we can conclude that NS1 protein
down-regulates the export of its own mRNA and that this
regulation requires the RNA-binding activity of NS1.
A temperature sensitive phenotype was found for transport
of NS1 mRNA with mutants NS1 81 and 11C. Thus, while
the phenotype obtained at 328C was indistinguishable from
wt, the export of NS1 mRNA was very eﬃcient at
restrictive temperature (Figure 7, NS1 81; 11C). Contrary
to the results for NS1 mRNA splicing (Table 1),
Figure 6. Eﬀect of NS1 mutations on the accumulation of NS-encoded
mRNAs. Cultures of HEK293T cells were transfected with the
appropriate plasmids to establish the indicated wt or mutant NS
replicons. Cells containing the NS1 81 replicon were incubated at either
permissive (32) or restrictive (39) temperature. At 36h post-transfection
total RNA was extracted and the poly A-containing RNA was selected
by oligo dT-cellulose chromatography. The amounts of NS1 and NEP
mRNA were determined by RNAse-protection assay using a probe
overlapping the ﬁrst exon and the intron sequences (probe). The
protected fragments were separated by polyacrylamide-urea gel
electrophoresis, revealed by autoradiography and quantitated in a
phosphorimager. The results obtained for mutant NS1 81at permissive
temperature are shown to the right after longer exposure. The mobility
of the probe and the protected fragments is indicated to the right and
the position of molecular weight markers is shown to the left.
Table 1. Ratio of NS1 and NEP mRNAs





wt (328C) 30 70 8.9
wt (398C) 93 7 3.7
NS1 2 98 1.2
81 (328C) 26 74 5
81 (398C) 85 15 8.7
R38A/K41A 498 52 1.2
aPercent of total NS segment mRNA.
bStandard deviation.
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replicon was not aﬀected at high temperature (Figure 7;
Table 2), thereby verifying that mutants NS1 81 and 11C
are temperature-sensitive for the block of NS1 mRNA
export.
DISCUSSION
In this report, we have analysed the consequences of NS1
protein expression in the splicing and nucleo-cytoplasmic
transport of NS transcripts using a transient system for
the replication and transcription of a recombinant
inﬂuenza virus NS replicon. This is a convenient system
that can be used as a model of the situation of an infected
cell. Indeed, the experimental approach used is a devel-
opment of the ampliﬁcation in vivo of transcriptionally
active viral mini-RNPs employed in the past for structural
studies (2,54,55). Furthermore, full-length RNPs gener-
ated in a similar way have been rescued into infectious
virus (44,46). Here we show that NS replicons can be
transiently ampliﬁed and express both NS1 and
NEP(NS2) proteins in proportions and to levels similar
to those produced in the virus infection (Figures 2–4).
We felt that this should be a convenient system to carry
out a genetic analysis of the role of NS1 in the maturation
and export of viral transcripts as the studies could be
made independent of other possible phenotypes described
for NS1 mutants. Thus, mutants NS1 81 and 11C show
predominant alterations in late virus gene expression and
particle formation (44,46), aspects not relevant in the
experimental setting used here. On the other hand, a
NS1 virus mutant is diﬃcult to handle in a cell line with
a normal interferon response (56) but can be studied
normally in a transient situation as the one described here.
Although it has been reported that the presence of
NEP(NS2) protein inhibits viral RNA replication in
a similar recombinant system (57), we consider this eﬀect
non-relevant to our studies, that deal with the post-
transcriptional processing and export of viral mRNAs.
The results presented here indicate that NS1 protein
inhibits the splicing of the NS collinear transcript in a
RNA-independent manner, as mutant NS1 R38A/K41A
behaves as wt (Figure 6; Table 1), and preferentially
blocks the nucleo-cytoplasmic export of NS1 mRNA by a
mechanism dependent on NS1–RNA interaction, since
mutant NS1 R38A/K41A permits an eﬃcient export of
this mRNA (Figure 7; Table 2). Although cells in which a
mutant NS R38A/K41A has been established accumulate
large amounts of NS1 mRNA and very little NEP(NS2)
mRNA in their cytoplasms (Figures 6 and 7), quasi-
normal synthesis of NEP(NS2) protein is produced
(Figures 2 and 3B). This apparent contradiction can be
explained by the fact that, at early times in the replication
and transcription of the NS R38A/K41A replicon, no NS1
protein is present in the system. Until NS1 protein is
accumulated to the required intracellular levels, eﬃcient
splicing of the collinear transcript is to be expected, as this
is the situation with a NS NS1 replicon (Figure 6).
Nevertheless, to account for the observed levels of
NEP(NS2) synthesis it would be necessary to invoke a
preferential translation of NEP(NS2) mRNA. It is
conceivable that NEP(NS2) mRNA is eﬃciently incorpo-
rated into the cell translation machinery because it is
generated at the early phase of the replicon gene
expression. On the contrary, NS1 mRNA is produced at
later times, when NS1 protein has accumulated. At that
point a large fraction of the cell-derived mRNA is being
used for virus-induced cap-snatching and incorporation of
new mRNAs into the cell translation machinery might be
aﬀected. In addition, the level of NS1 protein present in
each setting may inﬂuence the translation ability of the
NEP mRNA present (19,30,31). Thus, when NS1 is not
expressed (NS1 replicon), translation of NEP mRNA
might be much less eﬃcient than in those cases in which
NS1 protein is abundantly expressed, as for instance in
cells harbouring the wt NS replicon.
The eﬀects of NS1 in the splicing and nucleo-
cytoplasmic transport of mRNAs have been studied
previously by several groups, including ours, but the
analyses were carried out in vitro or using as targets
cellular mRNAs or viral ORFs expressed as RNA
polymerase II transcripts, but not true virus transcripts.
Figure 7. Eﬀect of NS1 mutations on the nucleo-cytoplasmic transport
of NS-encoded mRNAs. Cultures of HEK293T cells were transfected
with the appropriate plasmids to establish the indicated wt or mutant
NS replicons. Cells containing the NS1 81 or the 11C replicons were
incubated at either permissive (32) or restrictive (39) temperature. At
36h post-transfection the cells were fractionated into nuclear and
cytoplasmic fractions. Total RNA was extracted from each fraction and
the poly A-containing RNA was selected by oligo dT-cellulose
chromatography. The amounts of NS1 and NEP mRNA were
determined by RNAse-protection assay using a probe overlapping the
ﬁrst exon and the intron sequences (probe). The protected fragments
were separated by polyacrylamide-urea gel electrophoresis, revealed by
autoradiography and quantitated in a phosphorimager. The mobility of
the probe and the protected fragments is indicated to the right and the
position of molecular weight markers is shown to the left.
Table 2. Nucleo-cytoplasmic distribution of NS1 and NEP mRNAs
NS Replicon NS1 mRNA NEP mRNA
Nucleus Cytoplasm SD







wt (328C) 42 58 4.8 28 72 4.3
wt (398C) 43 57 4.9 n.d n.d –
NS1 18 82 4.2 6 94 2.5
81 (328C) 33 67 2.5 26 74 4.1
81 (398C) 13 87 4.8 54 496 1.5
R38A/K41A 16 84 3.7 n.d n.d –
11C (328C) 28 72 4.1 54 496 2.1
11C (398C) 6 94 1.5 52 498 1.2
aPercent of total NS1 or NEP cellular mRNA.
bStandard deviation.
n.d. not applicable.
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forward along the years for the inhibition of pre-mRNA
splicing by NS1: (i) From the results of in vitro
experiments it was ﬁrst proposed that the binding of
NS1 to a speciﬁc motif in U6 snRNA would impede
proper formation of U6-U2 and U6-U4 snRNP interac-
tions, leading to the block of the splicing reaction (26,40).
Such inhibitory interaction was postulated to occur in
splicing reactions on cellular pre-mRNAs but not on viral
mRNAs (40). This model would not explain the altera-
tions induced by NS1 in the use of alternative splice sites
(41) and is not supported by the results presented in this
report, as we show that NS1 protein indeed inhibits the
splicing of a true viral pre-mRNA (the NS collinear
transcript) and the RNA-binding activity of NS1 is not
required for such inhibition (Figure 6). (ii) After reporting
that the eﬀector domain of NS1 protein binds the 30 kDa
subunit of CPSF and blocks cellular mRNA cleavage and
polyadenylation (33), it was proposed that the splicing
inhibition by NS1 would be an indirect consequence of the
failure in 30-end processing, as the deﬁnition of the exon in
a single-exon containing mRNA depends on the 30-end
polyadenylation (42). This model would explain the
inhibition of cellular mRNA splicing and the lack of
such inhibition for intron-containing viral mRNAs (40),
since the 30-polyadenylation of the latter is carried out by
polymerase stuttering (58). Again, our results do not
support the proposed model, as NS1 protein indeed blocks
the splicing of the NS collinear transcript and a NS1
mutant lacking the eﬀector domain fully inhibits the
splicing of its own mRNA (Figure 6).
We cannot rule out the possibility that NS1 inhibition
of cellular mRNA 30-end formation would indirectly aﬀect
the splicing of cellular pre-mRNAs, but the results
presented here suggest that NS1 protein would inhibit
splicing by a more general mechanism. The interaction
with NS1–BP, a human protein involved in splicing (35) is
one possibility, while a de-regulation of the phosphoryla-
tion state of SR proteins is an alternative that would
explain the modiﬁcation in alternative splice site usage by
NS1 expression (41). A general inhibition of the splicing
machinery would be in line with the changes in the
localization of snRNPs induced by NS1 expression or
virus infection (59) and could be considered as part of the
viral response to inhibit the expression of cellular antiviral
factors (60). Whatever the mechanism involved, our
data indicate that inhibition would be mediated by
the N-terminal region of NS1 but would not require
NS1–RNA interactions (Figure 6).
As indicated earlier, the nucleo-cytoplasmic transport
of mRNAs is inhibited by expression of NS1 from cloned
DNA (25,28,41) and a model has been proposed for such
inhibition based upon the interaction of NS1 with the
30kDa subunit of the CPSF and the subsequent inhibition
of 30-end mRNA processing (33). In addition, the
interaction of NS1 with nuclear PABPII would block
the export of mRNAs that could partially escape from the
inhibition of 30-end formation (34). This model suggested
that the export of true viral mRNAs would not be aﬀected
by this transport block because their poly A-tails are
produced by the viral polymerase in a way independent of
normal cell mRNA polyadenylation (58). In addition, the
interaction of NS1 with the TAP/p15 pathway for mRNA
export has been recently described (61), leading to the
block of transport of cellular mRNAs that have under-
gone splicing. However, the results shown in this report
indicate that a preferential block of NS1 mRNA export is
produced when NS1 is expressed from a NS replicon and
further suggest that the RNA-binding activity of NS1 is
required for the inhibition of viral mRNA export
(Figure 7). These results suggest that, in addition to
the block of cellular, spliced mRNA export, mediated
by the inhibition of cellular mRNA 30-end processing (33)
or by targetting the TAP/p15 mRNA export pathway (61),
NS1 knocks down the export of its own virus mRNA, a
non-spliced mRNA, by RNA-binding. The mechanism
for this nuclear retention is not clear at this point in time
but a recent publication showing that nuclear export of
some virus mRNAs, including NS1 mRNA, requires their
association to the cellular transcription machinery might
shed some light (53). Thus, NS1 might act by avoiding the
coupling of the viral transcription events to the RNA
polymerase II complex after virus RNP-mediated cap-
snatching and hence interfering with the association
of shuttling hnRNP proteins to the virus transcripts.
This interference would not take place on the spliced
NEP(NS2) mRNA because it would associate to the
standard EJC/TAP-p15-dependent mRNA export
pathway (62).
The nuclear retention of NS1 mRNA could be a way to
improve the possibilities for this collinear transcript to
form a spliceosomal complex in the context of general
splicing inhibition described above. Thus, complete
inhibition of the splicing of the NS collinear transcript
would be deletereous for virus infection, as no NEP(NS2)
protein would be formed, and the virus might have
evolved an escape mechanism to avoid a complete block of
viral mRNA splicing. Such scenario is compatible with the
phenotypes observed in the genetic analysis presented
here. When NS1 protein is not expressed (NS1), no
inhibition of splicing and export is produced, the collinear
NS1 transcript is almost fully spliced and NEP(NS2)
mRNA is eﬃciently exported. If a RNA-binding mutant
of NS1 is expressed, splicing inhibition persists but the
export block is eliminated because no RNA recognition
can take place, leading to an eﬃcient export of collinear
NS transcript.
In summary, the results presented in this report
demonstrate that NS1 regulates the splicing and nucleo-
cytoplasmic export of its own collinear mRNA, in
addition to the previously reported inhibitions of cellular
mRNA processing and export. The simplest interpretation
of these results implies that the mechanisms for splicing
and export inhibition are distinct and at least in part
diﬀerent from the way NS1 appears to alter cellular
mRNA metabolism.
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